ASHM @ CROI 2016

John Brooks from the CDC in Atlanta provided an update on the HIV outbreak first identified in Indiana in December 2014. I reported on his first updat

Intensive cervical cancer screening may be appropriate for HIV-positive women with a CD4 count below 500 and for immunosuppressed solid organ transpla

HIV infection is an independent risk factor for osteoporosis. Initiation of ART induces additional 1-6% loss in bone mineral density (BMD). ART-associ

Five of 404 men who have sex with men (MSM) or transgender women taking a maraviroc-containing preexposure prophylaxis (PrEP) regimen or tenofovir/emt

Just a short not re PrEP implant - Poster 879 Looks like a implanon - looks easy to insert and to remove - Initially seems to deliver effective drug

The Dapivirine vaginal ring empowers women by giving them a device that they can use to protect themselves from HIV infection and which in no way requ

Wednesday 23rd Feb Session TD-12 It’s Complicated: Renal Function and STIs in PrEP Users. STI Data From Community-Based PrEP: Implementation Suggest

Session 0-4 Complications from Head to Toe Early Antiretroviral Therapy Does Not Improve Vascular Function: A START Substudy. Abstract 41 Presenter:

Alternative PrEP Regimen Maraviroc + FTC may be the first alternative PrEP regimen to become available. Obviously this is great for people who for so

It’s amazing how far we have come in the potential of neutralizing monoclonal antibodies against HIV. John Mascola from the Vaccine Research Centre ga

GS - US- 311-1089   Switching Tenofovir DF to Tenofovir Alafenamide in virally suppressed patients 48 week data was presented; RCT, double

Tuesday plenary 2 - A great overview of the current situation and where we are headed 90 90 90 are high targets Integrases will help achieve these

A brief blog reviewing the Bernard Fields Lecture. Monday 22nd Feb. T Cells Control of HIV: Implications for Vaccines and Cure. Speaker: Dr Bru

The use of Monoclonal antibodies in HIV therapy seems to be close at hand. The first plenary of the conference focussed on this. First potential comp

This paper reviewed the increase in viral suppression and sustained viral suppression in USA adults on ART between 2009 and 2013. Viral suppression i

Sydney Rosen presented this SA randomised trial. Patients in South Africa were randomised to start ART on first visit or delay to standard guidelines

The slight loss in bone mineral density associated with HIV PrEP antiretroviral use is reversible in young adult patients who stop taking the drugs, a

This WHO consultation followed on immediately from the CDC. This was one of the data collection workshops aimed at feeding into the development of the

I found the case-based workshop on HCV quite useful. The session highlighted some of the difficult therapeutic scenarios with current DAAs. It al

Monday 22nd Feb Session MD – Panel Discussion on Stigma, Trauma and Stress: Considerations for HIV Research and Programs. Moderator: Morenike Ukpong

25th HIV Drug Resistance Workshop This is the second time I have attended this meeting. It was very different from last year. Considerable attention

First Conference session that I have attended.  really a preconference workshop for "young Researchers" Three perspectives HIV -ve African women